Presentation and Management of Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Experience.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder characterized by intravascular hemolysis. Real-world experience of PNH management is largely unreported. A retrospective analysis was undertaken based on medical records from six patients with PNH [two with aplastic anemia (AA)] treated at our center, Dicle University, Turkey. Diagnosis was based on granulocyte PNH clones, ranging from 93% to 66%. All patients had symptoms consistent with PNH. One patient was managed adequately with supportive measures only. Five were treated with the complement inhibitor eculizumab. Follow-up data (<1 year) were available in four cases (the fifth had received only three infusions by final follow-up). Hemoglobin level in these four patients increased from 4.1-7.2 g/dL to 8.3-13.0 g/dL. Lactate dehydrogenase, a marker for hemolysis, decreased profoundly in the two non-AA patients, with more minor improvements in the two AA patients. Weakness and fatigue improved in all eculizumab-treated patients. Four of the five treated patients became transfusion independent, including the patient given only three infusions. In the remaining case, a patient with AA, transfusion requirement decreased, and abdominal pain and dysphagia resolved. No adverse events occurred. PNH can be successfully managed in routine practice.
Department of Hematology, Dicle University , Diyarbakir, Turkey.
Mehmet Sinan
MS
Dal
Department of Hematology, Dicle University , Diyarbakir, Turkey.
Abdullah
A
Karakuş
Department of Hematology, Dicle University , Diyarbakir, Turkey.
Mehmet Önder
MÖ
Ekmen
Department of Hematology, Dicle University , Diyarbakir, Turkey.
Orhan
O
Ayyildiz
Hemolysis; aplastic anemia; eculizumab; paroxysmal nocturnal hemoglobinuria